Emerging research has also highlighted the role of other checkpoint molecules, such as lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin domain 3 (TIM-3), and T lymphocyte attenuator (BTLA), in further dampening T cell responses in ccRCC [22]. This evidence concerns the gene LAG3 and nonpapillary renal cell carcinoma.